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Abstract
Bone morphogenetic proteins (BMPs) are important regulators of iron metabolism affecting hepcidin expression. We have previously
shown that 2 genetic polymorphisms in different genes (histocompatibility complex class I-like transmembrane protein, hemojuvelin)
involved in the regulation of hepcidin expression pathways are associated with hypertension. In this study, we analyzed genetic
variation sites in BMP2 (rs235756, rs235768) and BMP4 (rs4901474) to get more evidence linking iron metabolism to hypertension
risk in the Finnish population.
The study included 321 hypertensive cases and 463 controls from the Tampere Adult Population Cardiovascular Risk study
cohort. Genotyping of polymorphisms was done by polymerase chain reaction using DNAs extracted from buccal swabs.
We found that men carrying the GG genotype of BMP2 rs235756 (A>G) polymorphic site had a 4.09-fold risk (conﬁdence interval
[CI] 1.61–10.39, P= .003) for hypertension at the age of 50 years compared with A-allele carriers. The risk was signiﬁcant in the age
groups of 45 and 40 years as well. In addition, the 15-year follow-up period of the same individuals showed that carriers of the GG-
genotype had also signiﬁcantly higher readings of both systolic (P< .001) and diastolic (P= .01) blood pressure during the follow-up
time. No signiﬁcant association between BMP2 rs235768 (A>T) and hypertension was found. BMP4 polymorphic site rs4901474
(T>C) also had an effect on hypertension. CC genotype carriers had a 1.48-fold risk (CI 1.03–2.13, P= .033) for hypertension at the
age of 50 years when compared with T-allele carriers.
In conclusion, BMP2 polymorphic site rs235756 was associated with hypertension in Finnish men. An effect of BMP4 polymorphic
site on hypertension was also found.
Abbreviations: ANG= angiotensin, ANOVA= analysis of variance, BMI= bodymass index, BMP= bonemorphogenetic protein, BP
= blood pressure, CAD= coronary artery disease, CI= conﬁdence interval, HFE= histocompatibility complex class I-like transmembrane
protein, HH = hemochromatosis, HJV = hemojuvelin, OR = odds ratio, PCR = polymerase chain reaction, PHE = periodic health
examination, SNP = single-nucleotide polymorphism, TAMRISK = Tampere Adult Population Cardiovascular Risk study.
Keywords: BMP, genetic variants, hypertension, iron1. Introduction
Hypertension is a substantial risk factor for cardiovascular
diseases, including coronary artery disease (CAD), stroke, left
ventricular hypertrophy, congestive heart failure, peripheral
vascular disease, renal failure, and aortic aneurysms.[1] In
consideration of the high prevalence of hypertension, it has alsoEditor: Leonardo Roever.
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1a huge impact on public health. A better understanding of genetic
factors of hypertension will be helpful in the prevention and
curing of the disease.
Bone morphogenetic proteins (BMPs) are signaling molecules
belonging to transforming growth factor-beta superfamily. Apart
from many other functions, they have a key role in iron
homeostasis. Affecting the expression of hepcidin, the regulator
hormone of iron homeostasis, mutations/genetic variation in
BMPs are believed to lead to iron-deﬁciency and iron-overload
syndromes.[2] The common single-nucleotide polymorphism
(SNP) variants in the BMP genes are rs235756 and rs235768
(BMP2) and rs490141 (BMP4).
We have previously shown the association between the
polymorphism of 2 different iron regulator proteins—major
histocompatibility complex class I-like transmembrane protein
(HFE) and hemojuvelin (HJV) genes and hypertension.[3,4]
However, the association between BMP2 and BMP4, and
hypertension has not been studied earlier. Instead, Milet
et al[5] tested association of BMP2 polymorphism with serum
ferritin levels with conﬂicting results in 2 different cohort sample
of C282Y homozygote hemochromatosis (HH) patients. Recent-
ly, Ji et al[6] found an association with plasma ferritin levels
and rs235756 in the BMP2 gene when they studied Australian
blood donors. Association was signiﬁcant, especially in male
donors.
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sites in BMP2 and BMP4 genes are associated with hypertension
in the Finnish (Tampere Adult Population Cardiovascular Risk
study [TAMRISK]) cohort.
2. Methods
2.1. Participants
The TAMRISK is a prospective, longitudinal population-based
health survey study in Tampere, a city in southern Finland, with a
population of 230,000. The data for the TAMRISKwas collected
from the periodic health examinations (PHEs) done for 50-year-
old men and women living in Tampere. The PHE included one
60-minute session with a public health nurse at the center’s health
examination unit as previously described.[3,7] TAMRISK data
include information of risk factors for hypertension: blood
pressure (BP), weight, lipid values and smoking, alcohol
consumption, diabetes, and family history of cardiovascular
diseases. Current and previous diseases were identiﬁed based on
self-report of diagnosis by a physician, including hypertension.
Cases in this study were the subjects who had hypertension and/
or CAD at the age of 50 years as diagnosed by a physician by
normal healthcare procedures. For most patients, physicians
diagnose hypertension when BP readings are consistently 140/90
mm Hg or above. For each case, at least 1 normotensive control
with the same sex and similar smoking habits were chosen from a
PHE cohort (n=6000). Smoking status was evaluated based on
self-reporting. Alcohol use was documented by individual
interviews using a structured questionnaire. Weekly alcohol
consumption was assessed distinguishing the amounts of beer,
wine, and liquor consumed, and was then calculated as unit/wk.
One unit corresponds to 12g of ethanol.
Buccal swabs for DNA extraction and a permission form to use
PHE data were collected by mail separately of the physical
examination during years 2006 to 2010. Informed consent was
obtained fromall participants.TheEthicsCommittees of theTampere
University Hospital and the City of Tampere approved the study.Table 1
Clinical characteristics of cases and controls of the study
population.
Clinical characteristics Cases (n=321) Controls (n=463) P
Age, y 50±0 50±0
BMI, kg/m2 28.4±5.0 25.2±3.5 <.001
Hemoglobin 146.4±13.2 143.8±12.8 .020
Cholesterol, mmol/L 5.39±0.95 5.40±0.88 .769
Triglycerides, mmol/L 1.49±1.15 1.17±0.69 <.001
HDL cholesterol, mmol/L 1.58±0.45 1.69±0.44 .002
LDL cholesterol, mmol/L 3.17±0.88 3.19±0.82 .710
Glucose, mmol/L 5.21±1.44 4.83±0.53 <.001
Systolic blood pressure, mm Hg 143.0±16.8 129.0±15.3 <.001
Diastolic blood pressure, mm Hg 92.7±9.0 84.3±9.6 <.001
Hypertension, % 100 0 <.001
Diabetes, % 13.4 0 <.001
Daily smokers, % 27.1 22.7 .154
Alcohol consumption, unit/wk 6.8 5.3 .007
Lipid-lowering drugs, % 14.7 3.2 <.001
Family history of hypertension, % 73.5 41.1 <.001
Sex (male), % 56.1 53.1 .416
Data are presented as mean± standard deviation.
BMI=body mass index, HDL=high-density lipoprotein, LDL= low-density lipoprotein.2.2. DNA genotyping
DNA was extracted from buccal swabs using a commercial kit
(Qiagen Inc., Valencia, CA). Polymerase chain reaction (PCR)
was performed in a ﬁnal volume of 5mL containing 10ng of
sample DNA, 0.05mL of custom SNP-speciﬁc Assay mix, and
2.18mL of Taqman Universal PCRMasterMix. The Assay mixes
used were C___2513516_10 (rs235756), C___2244893_10
(rs235768), and C___7844917_10 (rs4901417). Ampliﬁcation
proceeded for 40 cycles of 15seconds at 95°C and 60seconds at
60°C. Genotyping followed the Applied Biosystems (Pleasanton,
CA) protocol. Automatic genotype call was performed after PCR,
by scanning plates on the 7900 HT Fast Real-Time PCR, which
provides the SDS2.3 software (Applied Biosystems).
2.3. Statistical analysis
Hardy–Weinberg equilibrium of the genotypes was calculated
using online encyclopedia calculator for genetic epidemiology
studies.[8]T test and 1-way analysis of variance (ANOVA) for
continuous variables (clinical characteristics), and chi-square test
for categorical variables (hypertension, CAD) were applied for
the comparison of BMP genotype groups. Associations of the
genotyped BMP2 and BMP4 gene variants with hypertension/
coronary artery disease with risk factors (BMI, sex, smoking2[years], and alcohol consumption [unit/wk]) were analyzed using
logistic regression analysis. The ANOVA was used to assess the
differences in mean BPs between genotypes at the age of 35, 40,
45, and 50 years. The model included the main effects of group
factor and time, and their interaction. Statistical analyses were
assessed using IBM SPSS Statistics 23, and the statistical
signiﬁcance was set to 0.05.3. Results
Clinical characteristics of the middle-aged (50±0 years) study
participants are listed in Table 1. Brieﬂy, case group comprised
321 hypertensive cases and control group 463 normotensive
subjects with the same sex distribution and similar smoking
habits. A total of 22 subjects were found to have CAD at the age
of 50 years.
Genotyping was successful in 756 subjects for the BMP2
rs235756 (A>G), in 784 subjects for the rs235768 (A>T), and in
766 subjects for the BMP4 rs4901474 (T>C). In the study
population, genotype distribution of the rs235756 in the BMP2
gene was 37% AA, 48%AG, and 15%GG, and of the rs235768
it was 33% TT, 48% TA, and 19% AA. Genotype distribution
for BMP4 rs4901474 was 31% TT, 50% TC, and 19% CC. The
measured genotype frequencies were not signiﬁcantly different
from the expectations of Hardy–Weinberg equilibrium (x2=
0.613 for rs235756, x2=0.432 for rs235768, and x2=0.204 for
rs4901474).
In the whole study population, at the age of 50 years, the BMP2
SNP rs235756 (A>G) associated signiﬁcantly with hypertension
(P= .035). More detailed analysis showed that individuals
carrying the GG genotype had more often hypertension (47%)
compared with the AG or AA genotype carriers (36.9% and
45.1%, respectively). Statistically signiﬁcant difference was
found only between GG and AG genotype carriers (P= .047),
and when A-allele carriers were combined, only a trend for
hypertension risk was found (P= .152). When men and women
were analyzed separately, we found that the risk for hypertension
was signiﬁcantly higher only among men (P= .035 for genotype
effect and P= .016 for GG vs A-allele). In the latter analysis,
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compared with 37.8% of A-allele carriers. We also found a
higher susceptibility to hypertension incidence already when the
same men were 10 years younger. At the age of 40 years, 19% of
the GG genotype carriers had hypertension compared with 8.1%
of the A-allele carriers (P= .019, for genotype effect P= .006).
Multivariate logistic regression with A-allele as reference
(adjusted with BMI, smoking history [years] and alcohol
consumption [unit/wk]) showed that at the age of 50 years,
the risk for hypertension was 4.09-fold in GG-genotype carriers
(conﬁdence interval [CI] 1.61–10.39, P= .003), at the age of
45 years it was 3.14 (CI 1.03–9.55, P= .043), and at the age of
40 years it was 2.55 (CI 1.13–5.72, P= .024). As expected, no
statistically signiﬁcant association was found between genotypes
and hypertension at the age of 35 years due to small amount of
hypertension cases. In women, no statistically signiﬁcant
association with hypertension at any age group was found.
In addition, 15-year follow-up period (35, 40, 45, and
50 years) of the same individuals showed that carriers of the
GG genotype had also signiﬁcantly higher readings of both
systolic (P< .001) and diastolic (P= .01) BP during the follow-up
time (Table 2, Fig. 1). Finally, we also analyzed association of this
polymorphismwith diagnosed CAD in men. Although there were
only 22 men who had CAD at the age of 50 years, those carrying
the GG genotype tended to have more often CAD than A-allele
carriers (11.5% vs 4.1%, respectively; P= .027).
For the other polymorphic site of the BMP2 gene (rs235768),
no statistically signiﬁcant association with hypertension or CAD
was found (data not shown).
No signiﬁcant association between BMP4 rs4901474 (T>C)
variants and hypertension was found (P= .092) in the whole
study population. However, after combining the T-allele carriers,
we found that 52.1% of the rare genotype CC carriers had
hypertension at the age of 50 years compared with 42.3% of the
T-allele carriers (odds ratio [OR] 1.48, CI 1.03–2.13, P= .033).
When BMI, smoking history (years), and alcohol consumption
(unit/wk) were included into analyses, risk for hypertension
among CC carriers was even higher (OR 2.00, CI 1.21–3.32,
P= .007). At the age of 45 years, risk for hypertension was still
signiﬁcant (OR 1.98, CI 1.02–3.82, P= .043), but disappeared at
the age of 40 and 35 years.Table 2
Means of systolic and diastolic blood pressures at different ages ac
Syst Diast Syst
rs235756 AA AG
Age 50 135.1±17.5 88.4±10.0 133.5±16.2 8
Age 45 132.5±13.6 85.3±9.2 131.3±14.7 8
Age 40 128.9±13.1 83.1±9.9 129.3±12.4 8
Age 35 127.7±12.6 81.5±10.1 127.5±12.8 8
rs235768 AA AT
Age 50 134.6±18.1 87.9±10.9 134.4±16.8 8
Age 45 132.7±16.4 84.7±10.4 133.0±14.9 8
Age 40 129.8±13.6 83.5±10.9 129.7±13.0 8
Age 35 127.9±12.7 80.7±10.5 128.3±12.8 8
rs4901474 TT TC
Age 50 134.4±16.3 87.6±9.8 135.2±17.1 8
Age 45 133.1±15.0 84.7±9.3 132.7±14.5 8
Age 40 131.1±13.3 84.1±9.1 130.5±12.5 8
Age 35 129.1±13.6 82.0±8.5 128.8±12.6 8
Data are presented as mean± standard deviation.
3No statistically signiﬁcant association with CAD was found
for BMP4 gene rs4901474.4. Discussion
In the present study, we found a signiﬁcant association between
hypertension and genetic variation of the BMP2 gene (rs235756).
Furthermore, a slight effect of BMP4 polymorphic site
(rs4901474) on hypertension was found. The risk for hyperten-
sion was signiﬁcantly higher within men in age groups of 40, 45,
and 50 years for GG genotype of SNP rs235756. Both systolic
and diastolic BPs were also signiﬁcantly higher among GG
genotype carriers already at the age of 35.
Bone morphogenetic proteins have earlier been found to have
role in human development and 2 vascular disorders—pulmo-
nary arterial hypertension and hereditary hemorrhagic telangi-
ectasia.[9] Moreover, a number of BMPs are up-regulated at sites
of vascular injury and atherosclerotic plaques, suggesting
that BMPs could play a role in regulating normal vascular
homeostasis and disease-associated vascular pathology. In
addition, different studies have revealed major role for the
BMP family of ligands and receptors in iron homeostasis. BMP
signaling in vascular development and cardiovascular diseases
have recently been excellently reviewed by Morrel et al,[10] and
Lowery and deCaestecker.[11]
Bone morphogenetic proteins are also involved in iron
homeostasis regulation, and in liver, they act as coreceptors of
HJV. Activation of the HJV-BMP signaling pathway leads to
transcription of hepcidin, which is the major known regulator of
systemic iron homeostasis. By reducing dietary iron uptake and
release from macrophages, hepatocytes, and other cell types, it
affects the amount of systemic iron.[12] In 2003, hepcidin
deﬁciency was revealed as a cause of iron overload. HH patients
with HJVmutations also had low levels of serum hepcidin[13] and
HH patients with HFE mutations had lower expression of
hepcidin in the liver compared with controls.[14] In addition of
HJV-BMP pathway, there are other pathways affecting hepcidin
expression as well. We have previously found an association
between hypertension and 2 iron metabolism regulator proteins,
HFE and HJV.[3,4] The present study is consistent with the earlier
ﬁndings.cording genetic variants.
Diast Syst Diast Syst Diast
GG P
6.8±10.0 139.1±18.8 89.8±10.2 .009 .011
4.2±9.5 137.4±20.0 86.5±10.6 .002 .084
2.9±9.6 132.8±15.0 85.5±10.9 .037 .063
1.7±9.3 132.9±13.9 83.7±10.3 .002 .191
TT P
7.5±9.7 135.5±17.3 88.0±10.5 .696 .747
5.2±9.3 131.7±14.8 84.4±9.5 .587 .647
3.4±10.0 129.1±12.5 82.9±9.1 .804 .786
2.4±9.6 128.8±13.5 81.9±9.3 .829 .275
CC P
7.8±9.8 136.5±16.3 89.2±9.6 .481 .260
5.4±9.3 131.9±13.4 86.1±9.5 .756 .415
3.7±9.6 131.0±13.4 84.5±13.0 .872 .728
2.1±9.5 129.7±12.9 84.0±10.0 .839 .181
Figure 1. Differences in mean systolic (P< .001) and diastolic (P= .01) blood pressure between BMP rs235756 genotypes (A>G) during 15 years of follow-up in
men. P values are from repeated-measures analysis.
Piesanen et al. Medicine (2017) 96:51 MedicineAssociation with BMP2 and BMP4, and hypertension has not
been studied earlier. Instead, the straight effects of BMPs on iron
metabolism have been under interest. Mutations of BMPs are
believed to lead to iron deﬁciency or overload syndromes.[2] Milet
et al. found that the polymorphic site of BMP2 (rs235756) is
associated with higher serum ferritin levels in HFE p.C282Y
homozygous patients,[5] but they were not able to replicate the
results in a later study.[15] They found that the highest serum ferritin
levelswereamongTT (AA) genotypes,whereas ourﬁndings suggest
that the highestBPswere amongGGgenotype carriers. Therefore, a
linkwith high ferritin and BPmay not be speculated in this context.
However, since their studies included only p.C282Y homozygous
patients, the results of the studies cannot be fully comparedwith our
present study. In Australian blood donors, BMP2 gene variants
were also found to associate with ferritin levels, especially in male
donors, but it was not possible to determine the signiﬁcance of
homozygosity and heterozygosity of the variant allele due to
insufﬁcient statistical power.[6]
Our recent ﬁnding suggests the possible role of BMPs in
essential hypertension, which may be linked with iron metabo-
lism. Male patients with essential hypertension have been found
to have increased serum ferritin levels when compared with
normotensive individuals, and a strong association between
hepcidin levels and serum ferritin has been observed.[16] This
underlines the possible effect of altered iron metabolism on
hypertension, although other BMP-mediated mechanisms cannot
be excluded.
A limitation of the study population is the lack of information
about diet, which has an important role in iron metabolism.
However, since the average daily iron intake for Finnish people is
near the national recommendations[17] and our study population
is quite large, we believe that there are no signiﬁcant differences
for daily dietary iron among the study population. However, it is
known that different genetic polymorphisms affect iron absorp-
tion and iron levels in the body. In Finland, markers of body iron
stores, serum ferritin, and transferrin saturation are not routinely
measured, and therefore a limitation of the TAMRISK study
population is the lack of these saturation markers.
The mechanism between iron metabolism and hypertension
are currently under study. Although the ﬁeld of ironmetabolism4regulation is far from being understood, hepcidin has been
assumed as being the primordial regulator of iron homeostasis.
Therefore, our focus is now to investigate the possible role of
hepcidin in regulation of BP.[3,4] Possible connection of the
rennin-angiotensin system and iron metabolism is supported by
the observations that angiotensin (ANG) II administration
caused 4.7-fold increase in the amount of hepcidin mRNA
concentration in the rat kidney, and that this increase could be
suppressed by the concomitant administration of losartan.[18]
An opposite effect was found in the hepatic hepcidin mRNA
expression and serum hepcidin concentration in ANG II-
induced hypertensive mice.[19] However, possible hepcidin-
renin-angiotensin system in hypertension warrants further
study.5. Conclusions
In conclusion, there was a signiﬁcant association in men between
BMP2 genetic variant (rs235756) and hypertension in the
genetically homogeneous Finnish population. Those who carried
the rare GG genotype of the gene had higher risk for hypertension
already at the age of 40 years. There was also an association
between BMP4 (rs4901417) genetic variants and hypertension.
Our results suggest that genetic variation in iron metabolism-
related genes participating in hepcidin expression may have an
effect on hypertension.
The area of investigation is important, as there might be some
clinical consequences for the treatment of essential hypertension
as well. For example, the iron intake of hypertensive patients
would be needed to be assessed more thoroughly to achieve
optimal iron balance of these patients. In addition, there might be
a chance for some pharmacological applications as well. Still,
more investigation will be needed to conﬁrm the connection
between iron metabolism and essential hypertension.Acknowledgments
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